Author

N. Tuncbag

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Armutlu· 1 shared A. C. Aksu· 1 shared A. Cingoz· 1 shared A. Dansik· 1 shared A. Koyas· 1 shared A. Kusoglu· 1 shared A. P. Cribbs· 1 shared A. Senturk· 1 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 7 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Armutlu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Extracellular matrix sulfation in the tumor microenvironment stimulates cancer stemness and invasiveness

A. Kusoglu, D. Ornek, A. Dansik, C. Uzun, S. N. Ozkan, S. Sarica, K. Yangin, S. Ozdinc, D. Turan Sorhun, N. Solcan, E. C. Doganalp, O. Arlov, K. Cunningham, I. C. Karaoglu, S. Kizilel, , E. Ozturk

The paper shows that increased sulfation in tumor ECM promotes cancer stemness and invasiveness through FAK-PI3K-mTOR signaling and RTK activation.

bioRxiv · Oct 17, 2023Bioengineering

Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival

E. Ozyerli-Goknar, E. Y. Kala, A. C. Aksu, I. Bulut, A. Cingoz, S. Nizamuddin, M. Biniossek, F. Seker-Polat, T. Morova, C. Aztekin, S. H. A. Kung, H. Syed, N. Tuncbag, M. Gonen, M. Philpott, , T. Bagci-Onder

This study uses CRISPR/Cas9 screens to identify ASH2L as a key regulator of glioblastoma cell survival, with downstream effects on cell cycle and apoptosis.

bioRxiv · Aug 17, 2022 · PreprintCancer Biology

Context dependent isoform specific PI3K inhibition confers drugresistance in Hepatocellular carcinoma cells

K. Narci, D. C. Kahraman, A. Koyas, T. Ersahin, N. Tuncbag, R. Cetin Atalay

This study examines how isoform-specific PI3K inhibition affects drug resistance in hepatocellular carcinoma cells depending on PTEN status, showing synergistic and antagonistic effects with Sorafenib.

bioRxiv · Mar 17, 2021Cancer Biology

Quantitative proteomics identifies secreted diagnostic biomarkers as well as tumor-dependent prognostic targets for clear cell Renal Cell Carcinoma

A. Senturk, A. T. Sahin, A. Armutlu, M. C. Kiremit, O. Acar, S. Erdem, S. Bagbudar, T. Esen, N. Tuncbag, N. Ozlu

The paper uses quantitative proteomics to identify secreted biomarkers and prognostic targets in ccRCC, finding SPARC as a promising diagnostic marker and proposing a biomarker panel for prognosis.

bioRxiv · Feb 8, 2021Cancer Biology

Functional constraints on replacing an essential gene with its ancient and modern homologs

B. Kacar, E. Garmendia, N. Tuncbag, D. I. Andersson, D. Hughes

This study replaces the essential tufA gene in E. coli with extant and ancestral homologs, showing that functional transfer depends on the presence of tufB and evolutionary distance.

mBio · Sep 6, 2017Peer-reviewedEvolutionary Biology